Pulmatrix, Ruthigen deal

Pulmatrix will reverse-merge with Ruthigen, with Pulmatrix shareholders owning 81% of the surviving entity. The newco will focus on developing Pulmatrix’s inhaled therapeutic pipeline, including PUR0200. The inhaled dry powder formulation of a long-acting muscarinic receptor antagonist enabled by a non-lactose approach using Pulmatrix’s iSPERSE delivery technology is in Phase II testing to treat chronic obstructive pulmonary disease (COPD). ...